|
Synonyms: AK-112 | AK112 | Idafang® (China) | SMT-112 | SMT112
ivonescimab is an approved drug (China (2024))
Compound class:
Antibody
Comment: Ivonescimab (AK112/SMT112) is a first-in-class anti-programmed death-1 (PD-1)/VEGF-A bispecific monoclonal antibody. It was designed to simultaneously block both PD-1 and VEGF-mediated immunosuppression in the tumour microenvironment (TME) and inhibit the pro-angiogenic action of VEGF. Interaction of ivonescimab with VEGF-A increases the antibody's avidity for PD-1 and enhances the inhibitory effect on PD-1/PD-L1 signalling [5].
|
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes. China (2024) |
| International Nonproprietary Names |
|
| INN number | INN |
| 11809 | ivonescimab |
| Synonyms |
| AK-112 | AK112 | Idafang® (China) | SMT-112 | SMT112 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 1196 |
| Other databases | |
| GtoPdb PubChem SID | 496703366 |
| Search PubMed clinical trials | ivonescimab |
| Search PubMed titles | ivonescimab |
| Search PubMed titles/abstracts | ivonescimab |
